Physician profile
Alexander Mule
NPI 1649744665
$29,478.84
in general payments reported to CMS, 2019-2025
38 companies · $3,173 in 2025
The $3,173 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,661 · 2022: $7,501 · 2023: $8,101 · 2024: $5,042 · 2025: $3,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Travel and Lodging: $9.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,306.93 |
| Travel and Lodging | $9.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,028.10 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $3,787.06 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $3,106.90 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,074.18 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $2,440.08 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $2,025.83 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Vanda Pharmaceuticals INC. | $1,882.11 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,556.50 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $1,075.57 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $958.09 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $792.25 | 2021-2022 | |
| Axsome Therapeutics, INC. | $747.03 | 2022-2025 | Auvelity |
| Corium, LLC | $607.35 | 2023-2025 | Azstarys |
| Noven Therapeutics, LLC | $491.13 | 2021-2025 | Xelstrym, Secuado |
| Almatica Pharma LLC | $345.24 | 2022-2024 | Loreev Xr, Sertraline Hcl |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $298.47 | 2021-2022 | |
| Indivior INC. | $289.47 | 2021-2025 | Sublocade, Perseris |
| Supernus Pharmaceuticals, INC. | $242.53 | 2022-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $233.59 | 2024-2025 | Cobenfy |
| Neuronetics, INC. | $232.30 | 2021 | |
| Idorsia Pharmaceuticals US INC | $219.39 | 2023-2024 | Quviviq |
| Eisai INC. | $157.05 | 2021-2022 | |
| Tris Pharma INC | $139.06 | 2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Livanova USA, INC. | $138.52 | 2022 | |
| Uswm, LLC | $92.48 | 2021 | |
| Merck Sharp & Dohme LLC | $86.28 | 2021-2023 | Belsomra |
| Bausch Health US, LLC | $83.99 | 2021-2025 | Aplenzin, Wellbutrin |
| Noven Pharmaceuticals, INC. | $57.90 | 2022-2023 | Xelstrym |
| Biogen, INC. | $48.22 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $39.70 | 2023 | Latuda |
| Adlon Therapeutics L.P. | $34.97 | 2021 | |
| Hologic Sales and Service, LLC | $29.59 | 2024 | Aptima |
| Allergan, INC. | $28.14 | 2021 | |
| Braeburn INC. | $25.83 | 2025 | Brixadi |
| Novo Nordisk INC | $23.83 | 2023 | Wegovy |
| Orexo US, INC. | $22.81 | 2021 | |
| Owp Pharmaceuticals, INC. | $20.80 | 2024 | Subvenite |
| Alfasigma USA, INC. | $16.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Mule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.